News

A potential AstraZeneca-Bristol Myers deal worth $400 billion would create one of the world’s largest drugmakers and combine major cancer franchises.

Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.

Pfizer stock has declined 27.7% over the past 5 years, yet the current valuation checks and market multiples now point to a picture that looks closer to fair than clearly cheap or expensive. The 5-year return of 27.7% in the red means long-term shareholders are still under water, which can make today’s pricing feel more attractive than it may actually be on fundamentals. Recent positive trial results for LITFULO in nonsegmental vitiligo and regulatory progress for vaccines and oncology...

There is more to this stock than meets the eye.

Amgen heads into Q2 earnings with a history of beats as investors watch key drug sales trends and seek updates on its MariTide obesity candidate.

Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.

Here is a way to get paid a meaningful income now on your Eli Lilly shares, income you keep no matter what the stock does, in exchange for agreeing to sell at a price above today's if it climbs there.

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

This blockbuster class of drugs is shattering all sales records. Which stock will do better—Eli Lilly or Novo Nordisk?

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

Rinvoq, Comirnaty and Opzelura have all received their own EC approvals this week.

Beyond analysts' top-and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

Strong sales of blood thinner Eliquis and newer drugs Camzyos and Reblozyl pushed second-quarter revenue to $12.97 billion, above analyst estimates

Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. Pfizer Value Investment Play Pfizer (NYSE:PFE) has seen its valuation drop […]

Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.

European Commission grants marketing authorization for Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for the 2026-2027 season in the EU. Approval covers use in individuals aged 6 months and older across all EU member states. Authorization supports advance manufacturing and supply ahead of the upcoming respiratory disease season. Pfizer, listed as NYSE:PFE, now has European Commission authorization for its XFG-adapted COVID-19 vaccine for the 2026-2027 season. The decision confirms that...

The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.

MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.

Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Not every fat dividend yield is worth chasing into retirement, and the difference between a durable income stream and a yield trap often hides in details most investors skip past entirely.

Retirement means living off your portfolio, not waiting for it to grow, and right now five familiar dividend giants are trading at prices that Wall Street considers deeply undervalued.

In the most recent trading session, Pfizer (PFE) closed at $25.25, indicating a +2.35% shift from the previous trading day.

Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.

One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.

Rep. Thomas Massie (R-Ky.) questioned Vice President JD Vance‘s silence after the Trump administration established billions for Pfizer Inc.‘s COVID-19 vaccine contracts for 2026 and 2027. On Sunday, Massie revived Vance’s COVID vaccine comments from the Joe Rogan podcast in...

AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms it.

Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.